BioPharmSignal logoBioPharmSignal

Biotech News

Alkermes plc Reports Second Quarter 2026 Financial Results

Alkermes plc (ALKS)Alkermes plcEarnings

DUBLIN --(BUSINESS WIRE)--Jul. 28, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at

Related news

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

PRAXPraxis Precision Medicines2026-08-06 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

TSHATaysha Gene Therapies2026-08-04 20:00 EST

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

ECORelectroCore2026-07-30 12:00 EST

electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026

View all latest news

Alkermes plc

Alkermes is a biopharmaceutical company focused on neuroscience, addiction medicine, and specialty therapeutics. Its portfolio combines commercial products and development programs across CNS and related areas.

Recent company news

ALKSAlkermes plc2026-07-28 11:00 EST

Alkermes plc Reports Second Quarter 2026 Financial Results

ALKSAlkermes plc2026-07-14 20:00 EST

Alkermes to Report Second Quarter Financial Results on July 28, 2026

ALKSAlkermes plc2026-07-13 11:00 EST

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

ALKSAlkermes plc2026-06-17 20:15 EST

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

ALKSAlkermes plc2026-06-15 11:00 EST

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Stock data

Close
48.37 USD
Market cap
6.89B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States